ClinicalTrials.gg
RecruitingNCT06489587Updated Jul 8, 2024

Creatine Supplementation At Simulated Altitude

An interventional study of Placebo and Creatine in Exercise Performance, sponsored by California Polytechnic State University-San Luis Obispo. Recruiting at 1 site in United States. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-08.

Sponsored by California Polytechnic State University-San Luis Obispo · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

Creatine supplementation has been shown to increase exercise performance at sea level. The goal of this study is to determine the effects of creatine supplementation on exercise performance at simulated altitude.

Read the detailed description

Military personnel often encounter harsh environments such as high altitudes and hypoxic conditions, leading to significant constraints on their exercise capacity and performance. At sea-level creatine supplementation increases exercise performance; however no experimental studies have examined the effect of creatine supplementation at simulated altitude. The overall objective of this study is to investigate the effects of creatine supplementation on exercise performance, via a repeated sprints test (Wingate Test) after a 2-day supplementation period, compared to a placebo group.

02

Conditions studied

  • Exercise Performance
03

In context

Lead sponsor

California Polytechnic State University-San Luis Obispo is the lead sponsor of 29 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-40 years old
  • 18.5 to 40 kg/m2
  • Habitually active (>150 minutes per week of moderate-vigorous physical activity)

Exclusion criteria

Exclusion Criteria:

  • Pregnant or trying to become pregnant
  • Recent use of creatine supplementation
  • Supplemental allergies
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Placebo Supplementation

    Participants given Placebo (20 grams of glucose) daily in 5-gram servings (4 capsules), 4 times per day for 2 days.

    Dietary Supplement: Placebo

  • Experimental
    Creatine Supplementation

    Participants given Creatine (20 grams of glucose) daily in 5-gram servings (4 capsules), 4 times per day for 2 days.

    Dietary Supplement: Creatine

Interventions

  • Dietary supplementPlacebo

    Participants given 40 grams of glucose in total to be taken over 2 days, in 5-gram servings (4 capsules), 4 times per day.

  • Dietary supplementCreatine

    Participants given 40 grams of creatine in total to be taken over 2 days, in 5-gram servings (4 capsules), 4 times per day.

06

What researchers measure

Primary outcomes

  1. Peak power

    Peak power is measured in watts.

    Time frame: Change from baseline to 3 days

Secondary outcomes

  1. Body Weight

    Body weight is measured in kilograms.

    Time frame: Change from baseline to 3 days

  2. Relative peak power

    Relative peak power is measured in watts per kilogram.

    Time frame: Change from baseline to 3 days

  3. Mean power

    Mean power is measured in watts.

    Time frame: Change from baseline to 3 days

  4. Relative mean power

    Relative mean power is measured in watts per kilogram.

    Time frame: Change from baseline to 3 days

  5. Fatigue index

    Fatigue index is measured in watts per second.

    Time frame: Change from baseline to 3 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data and documentation will be available under a data-sharing agreement. Information shared with outside collaborators will link data to two unique study identifiers (de-Identified) to maintain participant anonymity, and outside researchers and the community will not be allowed to have access to participant names and confidential information.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Seven years after the date of the last participant completing the study.

Access criteria: Contact PI and a date-sharing agreement will be created that provides for (1) a commitment to use the data for research purposes only; (2) a commitment to securing the data using appropriate computer technology (password protected and encrypted); (3) a commitment to destroying or returning the data after analyses are completed and (4) a commitment not to attempt to identify participants individually.

Data sharing details ↗ · healthresearch.calpoly.edu

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Jun 2025, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2024
First posted
Jul 8, 2024
StartActual
Jun 25, 2024
Primary completionEst.
Jun 2025
CompletionEst.
Jun 2026
Last update
Jul 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06489587
Lead sponsor
California Polytechnic State University-San Luis Obispo
Responsible party
Todd Hagobian (Chair and Professor, California Polytechnic State University-San Luis Obispo) — Principal investigator
First posted
Jul 8, 2024
Start date
Jun 25, 2024
Primary completion
Jun 2025 (estimated)
Completion
Jun 2026 (estimated)
Last update
Jul 8, 2024

Study contacts

Todd Hagobian, PhD
Contact
thagobia@calpoly.edu
8057567511
Todd Hagobian, PhD
principal investigator · California Polytechnic State University-San Luis Obispo

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Creatine

Start the discussion